Patent intelligence · US
US 2015017178
Anti-CD26 Antibodies and Uses Thereof
Anti-CD26 Antibodies and Uses Thereof
Patent details — US 2015017178
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 15, 2015
- Expiration
- Jan 10, 2035
- Applicant
- ADIENNE S R L S U [IT]
- CPC classes
- A61K 39/ 395 A I, A61K/393955, A61P/3706, A61P/706
Quick answer
US 2015017178 (Anti-CD26 Antibodies and Uses Thereof) is held by ADIENNE S R L S U [IT]. Status: granted. Granted Jan 15, 2015. Expires Jan 10, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ADIENNE S R L S U [IT]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 39/ 395 A I, A61K/393955, A61P/3706, A61P/706
Frequently asked questions
What is US patent 2015017178?
US 2015017178 (Anti-CD26 Antibodies and Uses Thereof) is held by ADIENNE S R L S U [IT]. Status: granted. Granted Jan 15, 2015. Expires Jan 10, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 2015017178?
ADIENNE S R L S U [IT] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1 pharmaceutical patents for this assignee.
When does US 2015017178 expire?
Our index shows an expiration date of Jan 10, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.